Noninvasive Cardiac Output Monitors: A State-of-the-Art Review

Paul E. Marik, MD, FCCM, FCCP

Despite improvements in resuscitation and supportive care, progressive organ dysfunction occurs in a large proportion of patients with acute, life-threatening illnesses and those undergoing major surgery. Recent data suggest that early aggressive resuscitation of critically ill patients may limit organ failure and improve outcome. In a landmark study, Rivers et al7 showed that a protocol of early goal-directed therapy reduces organ failure and improves survival in patients with severe sepsis and septic shock. Similarly, optimization of cardiac output (CO) in patients undergoing major surgery has been shown to reduce postoperative complications and the length of stay.8-13 By contrast, excessive fluid resuscitation has been associated with increased complications, increased lengths of intensive care unit and hospital stay, and increased mortality.14-17 These data suggest that fluid resuscitation should be titrated closely to minimize the risks of over- or under-resuscitation.18

Over the last 2 decades, the understanding of the complexities of shock has improved, and conventional approaches to resuscitation have come under increasing scrutiny. The traditional measured variables of resuscitation have included blood pressure, pulse rate, central venous pressure, and arterial oxygen saturation. These variables change minimally in early shock and are poor indicators of the adequacy of resuscitation.19 Furthermore, the clinical assessment of CO and intravascular volume status are notoriously inaccurate.20 With the increased recognition of the limitations of traditional methods to guide resuscitation, newer techniques have emerged that dynamically assess patients’ physiologic response to a hemodynamic challenge.

In patients with indices of inadequate tissue perfusion, fluid resuscitation generally is regarded as the first step in resuscitation. However, clinical studies consistently have shown that only about 50% of hemodynamically unstable patients are volume responsive.14 Therefore, the resuscitation of hemodynamically unstable patients requires an accurate assessment of the patients’ intravascular volume status (cardiac preload) and the ability to predict the hemodynamic response after a fluid challenge (volume responsiveness). Fundamentally, the only reason to give a patient a fluid challenge is to increase the stroke volume (SV) (volume responsiveness). If the fluid challenge does not increase the SV, volume loading serves the patient no useful benefit and is likely to be harmful. Therefore, the measurements of SV and CO are fundamental to the hemodynamic management of critically ill and injured patients and unstable patients in the operating room. Both fluid challenges and the use of inotropic agents/vasopressors should be based on the response of the SV to either of these challenges. Until recently, continuous real-time CO monitoring required a thermodilution pulmonary artery catheter (PAC). During the past decade, several less invasive methods have been developed. These technologies are reviewed in this article.

Adolph Fick described the first method of CO estimation in 1870.21 This method was the reference standard by which all other methods of determining CO were evaluated until the introduction of the PAC in the 1970s.22 Despite its limitations, CO measurement with a PAC using the bolus thermodilution method has become the de facto gold standard for the measurement of CO and is the reference standard used to compare noninvasive technologies.23,24 When assessing the reliability and clinical use of a noninvasive CO device, 2 factors are important: the accuracy of individual measurements compared with the reference standard and the ability to track changes in the SV and CO accurately and reproducibly after a therapeutic intervention. The latter is the most important factor when evaluating these devices because it directly impacts clinical decision making and therapeutic interventions. In most clinical situations, whether a cardiac index is 2.1 or 2.6 L/min/m² is not of great clinical importance; however, whether the change in the SV after a fluid bolus is 5% or 15% is of great clinical significance. The most frequently used analytic method for evaluating CO monitoring devices is the Bland-Altman method of plotting the bias against the mean CO and determining the limits of agreement (LOAs).25 The percentage error is calculated as the ratio of 2 standard deviations (SDs) of the bias (LOA) to the mean CO and is considered clinically acceptable if it is below 30%, as proposed by Critchley and Critchley.23 The Bland-Altman method only addresses how well the method being evaluated agrees with the reference method and fails to show whether the test method reliably detects changes in CO. Although the accuracy of noninvasive CO devices to measure trends in CO has not been standardized, a number of methods have been described in...
the literature, including the correlation coefficient, the Bland-Altman method, the 4-quadrant plot, and receiver-operator characteristic (ROC) curve analysis.\textsuperscript{24}

**CO AS MEASURED BY CARBON DIOXIDE REBREATHTHNG**

CO can be calculated by the CO\textsubscript{2} partial rebreathing technique using the modified Fick equation.\textsuperscript{21} NICO (Respironics, Murraysville, PA) is a proprietary device that measures CO based on this principle. The CO\textsubscript{2} partial rebreathing technique compares end-tidal carbon dioxide partial pressure obtained during a nonrebreathing period with that obtained during a subsequent rebreathing period. The ratio of the change in end-tidal carbon dioxide and CO\textsubscript{2} elimination after a brief period of partial rebreathing (usually 50 seconds) provides a noninvasive estimate of the CO.\textsuperscript{26} A limitation of the rebreathing CO\textsubscript{2} CO method is that it only measures pulmonary capillary blood flow (ie, the nonshunt portion of the CO). To calculate the total CO, intrapulmonary shunt and anatomic shunt factions (Qs/Qt) must be added to the pulmonary capillary blood flow. The NICO system estimates Qs/Qt using a shunt correction algorithm that uses oxygen saturation from pulse oximetry and the fractional concentration of inspired oxygen.

The CO\textsubscript{2} rebreathing technique has a number of significant limitations. Almost all the validation studies have been performed in patients undergoing anesthesia or in deeply sedated mechanically ventilated intensive care unit patients in whom the agreement with thermodilution CO has varied from “poor” to “acceptable.”\textsuperscript{27-32} In spontaneously breathing patients, the rebreathing period is associated with an increase in minute ventilation.\textsuperscript{33} This reduces the accuracy of the CO determinations.\textsuperscript{30,34} Furthermore, a low minute ventilation, high shunt fraction, and a high CO result in inaccurate measurements.\textsuperscript{27,29,34} Considering the limitations of this technology and the potential inaccuracies, the routine use of the CO\textsubscript{2} rebreathing technique to guide fluid and vasopressor therapy cannot be recommended.

**ESOPHAGEAL DOPPLER**

The esophageal Doppler technique measures blood flow velocity in the descending aorta by means of a Doppler transducer (4-MHz continuous wave or 5-MHz pulsed wave according to the manufacturers) placed at the tip of a flexible probe. The probe is introduced into the esophagus of sedated, mechanically ventilated patients and then rotated so that the transducer faces the descending aorta and a characteristic aortic velocity signal is obtained. The CO is calculated based on the diameter of the aorta (measured or estimated), the distribution of the CO to the descending aorta, and the measured flow velocity of blood in the aorta. Because esophageal Doppler probes are inserted blindly, the resulting waveform is highly dependent on correct positioning. The clinician must adjust the depth, rotate the probe, and adjust the gain to obtain an optimal signal.\textsuperscript{35} Poor positioning of the esophageal probe tends to underestimate the true CO. There is a significant learning curve in obtaining adequate Doppler signals, and the correlations are better in studies in which the investigator was not blinded to the results of the CO obtained with a PAC.\textsuperscript{36} A major limitation of esophageal Doppler monitoring is the assumption that a fixed percentage of the CO is directed to the head and descending aorta. Although this may be true in healthy volunteers, the present authors have shown that a disproportionate percentage of the increase in CO with fluid loading in hemodynamically unstable patients is directed into the carotid arteries.\textsuperscript{37} Therefore, the increase in blood flow velocity in the descending aorta may not correlate well with the increase in the SV. Nevertheless, esophageal Doppler monitoring has use in aiding in the assessment of the hemodynamic status and guiding fluid therapy in the operating room.\textsuperscript{10-12,38}

A completely noninvasive Doppler technology, the ultrasound CO monitor (USCOM, Sydney, Australia), uses transaortic or transpulmonary Doppler ultrasound flow tracings to calculate CO as the product of the SV and heart rate. The SV is calculated from a proprietary algorithm applying ultrasound principles of blood velocity–time integral (VTI) measurements in the ventricular aortic/pulmonary outflow tract. Studies comparing USCOM measurements of CO with those obtained by the standard thermodilution technique have shown mixed results.\textsuperscript{39-42} The use of Doppler ultrasound to determine the cardiac index has several inherent technologic limitations. Potential sources of variation exist in the estimation of the aortic/pulmonary outflow tract area, the determination of the VTI, and the variability with operator-dependent measurements. With USCOM, the aortic/pulmonary outflow tract area is not measured directly but rather calculated from a proprietary anthropometric algorithm based on the subject’s body height. The stroke distance is simply the distance a red blood cell travels per systolic stroke. This is measured as the VTI of the Doppler flow profile of each systolic stroke. Thus, the accuracy of the USCOM technology depends on obtaining accurate, reproducible VTI values. A precise VTI measurement requires a good flow signal and its correct interpretation, both of which are heavily dependent on the subject and the operator. An improper technique of poor Doppler ultrasound beam alignment with blood flow at the aortic/pulmonary outflow tract will lead to suboptimal VTI measurements. A further limitation of this technique is that it is not conducive to continuous monitoring.

**PULSE CONTOUR ANALYSIS**

The concept of pulse contour analysis is based on the relation among blood pressure, SV, arterial compliance, and systemic vascular resistance (SVR).\textsuperscript{43} The SV or CO can be calculated from the arterial pressure waveform if the arterial compliance and SVR are known. Although the 4 pulse contour systems that are available commercially use different pressure-volume conversion algorithms, they are based on this basic principle. These systems can be divided into 3 categories: (1) pulse contour analysis requiring an indicator dilution CO measurement to calibrate the pulse contour (ie, LiDCO System; LiDCO, Cambridge, UK; and PiCCO System; Pulsion, Munich, Germany), (2) pulse contour analysis requiring patient demographic and physical characteristics for arterial impedance estimation (ie, FloTrac System; Edwards Lifesciences, Irvine, CA), and (3) pulse contour anal-
increase in blood flow in the brachial artery. This may lead to the cerebral circulation with a significantly smaller percentage of the systolic portion of the arterial waveform. Furthermore, it has been shown that in volume-responsive patients there is selective redistribution of blood flow to the femoral artery. Discrepancies among different sites may be large, and in conditions of intense vasoconstriction, the radial blood pressure may underestimate the true aortic blood pressure, giving a falsely low CO value. The LiDCO system combines pulse contour analysis with lithium indicator dilution for continuous SV and SVV monitoring. The arterial pressure waveform is interpreted as a continuous curve describing the volume of the arterial tree in arbitrary units (standardized volume waveform). The effective value (approximately 0.7 times the original amplitude) of this volume waveform is determined using the root mean square, a mathematic principle to calculate the magnitude of a varying quantity. The root mean square value is called "nominal SV" and is scaled to an "actual SV" using a patient-specific calibration factor. This factor is derived from a lithium indicator dilution CO measurement and corrects for arterial compliance and variations among individuals. The lithium can be injected into a peripheral vein, and the doses do not exert pharmacologically relevant effects in adult patients. The LiDCO indicator dilution method has shown to be at least as reliable as other thermodilution methods over a broad range of CO in a variety of patients. Recalibration should be performed after acute hemodynamic changes and after any intervention that alters vascular impedance.

Lithium Dilution and Pulse Contour Analysis

The LiDCO system combines pulse contour analysis with lithium indicator dilution for continuous SV and SVV monitoring. The arterial pressure waveform is interpreted as a continuous curve describing the volume of the arterial tree in arbitrary units (standardized volume waveform). The effective value (approximately 0.7 times the original amplitude) of this volume waveform is determined using the root mean square, a mathematic principle to calculate the magnitude of a varying quantity. The root mean square value is called "nominal SV" and is scaled to an "actual SV" using a patient-specific calibration factor. This factor is derived from a lithium indicator dilution CO measurement and corrects for arterial compliance and variations among individuals. The lithium can be injected into a peripheral vein, and the doses do not exert pharmacologically relevant effects in adult patients. The LiDCO indicator dilution method has shown to be at least as reliable as other thermodilution methods over a broad range of CO in a variety of patients. Recalibration should be performed after acute hemodynamic changes and after any intervention that alters vascular impedance.

Transpulmonary Thermodilution and Pulse Contour Analysis

The PiCCO monitoring system combines pulse contour analysis with the transpulmonary thermodilution CO (TPCO) to determine a number of hemodynamic parameters. The TPCO requires both central venous (internal jugular or subclavian) and central arterial (femoral artery) catheterization. TPCO measurements with PiCCO have been shown to be reliable in comparison with PAC thermodilution in broad groups of patients. The continuous pulse contour SV is calculated from the area under the systolic portion of the arterial waveform. In addition, the shape of the arterial waveform (dP/dt), arterial compliance, SVR, and a patient-specific calibration factor are required for the calculation. Arterial compliance is derived from the SVR and the shape of the diastolic part of the arterial waveform. The PiCCO monitor uses TPCO measurement for calibration of the algorithm. The PiCCO calibration appears to remain accurate within 6 hours of calibration even when the vascular tone has changed. In addition, the thermodilution curve can be used to measure the global end-diastolic volume and extravascular lung water, a marker of pulmonary edema. The monitor also measures SVV/PPV, which has
been shown to be predictive of fluid responsiveness.\textsuperscript{55} In a randomized controlled trial, Mutoh et al\textsuperscript{56} showed an improved clinical outcome for patients with subarachnoid hemorrhage randomized to a PiCCO-based hemodynamic algorithm as compared with the “standard of care,” which used a PAC algorithm. Additional studies are required to evaluate the clinical benefit of this technology.

**Pulse Contour Requiring Patient Demographic and Physical Characteristics and No Calibration**

The FloTrac system consists of the FloTrac sensor and corresponding Vigileo monitor. The system is operator independent, needs no external calibration, and requires a peripheral arterial catheter only. The basic principle of the system is the linear relation between the pulse pressure and the SV. The SV is estimated using the following equation\textsuperscript{43}: $SV = SD AP \times \chi$. The arterial pressure waveform is sampled each 20 seconds at 100 Hz, which results in 2,000 data points. SD\textsubscript{AP} is the standard deviation of these data points and reflects the pulse pressure. The factor $\chi$ represents the conversion factor that depends on arterial compliance, the mean arterial pressure, and waveform characteristics. The patient’s vascular compliance is assessed using biometric values (ie, sex, age, height, and weight) according to the method described by Langewouters et al.\textsuperscript{57} Waveform characteristics assessed are skewness (degree of asymmetry) and kurtosis (degree of peakedness) of the individual arterial pressure curve. Skewness and kurtosis represent changes in the arterial waveform, which should reflect changes in vascular tone. The factor $\chi$ is recalculated every minute and enables calculation of the SV without external calibration.

Because the system is operator independent, easy to use, needs no external calibration, and only requires a peripheral arterial catheter (usually the radial artery), the FloTrac system has found popular appeal and has been studied widely, particularly in the setting of cardiac surgery. To date, the accuracy of FloTrac has been evaluated in 45 studies;\textsuperscript{58-102} these are summarized in Table 2. Studies evaluating the first-generation FloTrac showed poor agreement compared with intermittent thermodilution, which is the gold standard. Second-generation devices were purported to be more reliable; however, their accuracy remained clinically unacceptable. Furthermore, in patients with low SVR (eg, sepsis or liver failure), measurements were unreliable, with the bias being correlated with the SVR.\textsuperscript{65,95,99,101} The data from Table 2 show that the percentage error is lower in cardiac patients as compared with other cohorts (37% ± 11% vs 47% ± 11%, $p = 0.01$). The third-generation software claims to have overcome these problems. However, 6 recent validation studies evaluating this latest version do not show improved accuracy in comparison with older versions.\textsuperscript{97-102} More problematic is the fact that the system does not track changes in the SV accurately after a volume challenge or after the use of vasopressors.\textsuperscript{65,79,85,94,95,100,101,103} These limitations significantly restrict the clinical use of this device. The SVV may be useful in intraoperative fluid optimization in select noncardiac surgical patients.\textsuperscript{104} However, in a cohort of medical patients, it was reported that the SVV was poorly predictive of volume responsiveness.\textsuperscript{105} Takala et al\textsuperscript{106} randomized 388 hemodynamically unstable patients to noninvasive monitoring with the FloTrac system for 24 hours or usual care (the control group). The main outcome measure was the proportion of patients achieving hemodynamic stability within 6 hours of starting the study. Surprisingly, the time to reach the predefined resuscitation goals was longer in the FloTrac group, with worse clinical outcomes in these patients.

**Pulse Contour Requiring No Patient Data and No Calibration**

The MostCare system uses the pressure recording analytic method (PRAM) to determine the SV.\textsuperscript{107} PRAM measures the area under the curve of the arterial waveform. No external calibration or pre-estimated data are required. The morphology of the arterial waveform is analyzed to determine an internal calibration. This system uses high-time resolution by sampling the signal at 1,000 Hz, and it analyzes the whole cardiac cycle. The area under the pressure wave (P/t) is determined during the whole cardiac cycle. The PRAM methodology analyzes the pressure wave morphology and, in real time, identifies the diastolic phase from the dicrotic notch determination. The P/t is then divided into contributions from the diastolic phase and the systolic phase, with 2 impedances based on different characteristics. There are limited studies that have evaluated the accuracy of this system, with those published by the patent holder’s group showing good results,\textsuperscript{107-112} whereas independent studies have shown mixed results.\textsuperscript{113-115}

**Comparative Studies of the Pulse Contour Systems**

A number of studies have been performed comparing the accuracy of the 3 major pulse contour systems (none has compared the MostCare system). Unfortunately, many of these studies suffer methodologic problems in terms of the gold standard used (thermodilution) and the sample size. Hadian et al\textsuperscript{84} performed a cross-comparison of the CO and trending accuracy of the LiDCO, PiCCO, and FloTrac systems compared with intermittent PAC thermodilution.\textsuperscript{94} In this study, the performances of the PiCCO and LiDCO systems were adequate and comparable, whereas that of the FloTrac system was suboptimal. Monnet et al\textsuperscript{116} compared the changes in pulse contour–derived CO induced by a fluid challenge or norepinephrine in patients undergoing monitoring with the PiCCO or FloTrac systems. Although the PiCCO system accurately tracked the changes in volume- and norepinephrine-induced cardiac index (the area under the ROC curves = 0.878 and 0.924, respectively), the FloTrac system was less reliable (the area under the ROC curves = 0.564 and 0.541, respectively).

**Pulse Contour Analysis and Dynamic Preload Indices**

A number of studies, mainly those performed in a controlled setting in the operating room, have shown that the PPV derived from the analysis of the arterial waveform and the SVV derived from pulse contour analysis are predictive of fluid responsiveness.\textsuperscript{55} The principles underlying this technique are based on the physiologic changes that occur during positive-pressure ventilation.\textsuperscript{116} Intermittent positive-pressure ventilation induces cyclic changes in the loading
conditions of the left and right ventricles. Mechanical inflation decreases the preload and increases the afterload of the right ventricle. The reduction in the right ventricular preload and the increase in the right ventricular afterload both lead to a decrease in right ventricular stroke volume, which is at a minimum at the end of the inspiratory period. The inspiratory reduction in right ventricular ejection leads to a decrease in left ventricular filling after a phase lag of 2 or 3 heartbeats. Thus, the left ventricular preload reduction may induce a decrease in the left ventricular SV, which is at its minimum during the expiratory period. The cyclic changes in the right ventricular and left ventricular SV are greater when the ventricles operate on the steep rather than the flat portion of the Frank-Starling curve. Therefore, the magnitude of the respiratory changes in the left ventricular SV is an indicator of biventricular preload dependence. A PPV/SVV of greater than 12% to 13% has been reported to be predictive of volume responsiveness.55 It should be noted

Table 2. Accuracy of the FloTrac/Vigileo System

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Version Setting</th>
<th>Reference Method</th>
<th>Data Points</th>
<th>Bias</th>
<th>LOA</th>
<th>% Error</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chakravarthy</td>
<td>2007</td>
<td>1.01</td>
<td>Cardiac PAC</td>
<td>438</td>
<td>0.15</td>
<td>0.66</td>
<td>13</td>
</tr>
<tr>
<td>De Waal</td>
<td>2007</td>
<td>1.01</td>
<td>Cardiac PAC</td>
<td>184</td>
<td>0</td>
<td>—</td>
<td>33*</td>
</tr>
<tr>
<td>Manecke</td>
<td>2007</td>
<td>1.01</td>
<td>Cardiac PAC</td>
<td>295</td>
<td>0.55</td>
<td>1.96</td>
<td>39*</td>
</tr>
<tr>
<td>McGee</td>
<td>2007</td>
<td>1.01</td>
<td>Various-ICU PAC</td>
<td>561</td>
<td>0.2</td>
<td>2.38</td>
<td>43</td>
</tr>
<tr>
<td>Zimmerman</td>
<td>2008</td>
<td>1.01</td>
<td>Cardiac PAC</td>
<td>192</td>
<td>0.1</td>
<td>2.90</td>
<td>48*</td>
</tr>
<tr>
<td>Marque</td>
<td>2009</td>
<td>1.01</td>
<td>Cardiac PAC-CCO</td>
<td>33</td>
<td>—0.1</td>
<td>1.68</td>
<td>31*</td>
</tr>
<tr>
<td>Ostergaard</td>
<td>2009</td>
<td>1.01</td>
<td>Cardiac PAC</td>
<td>50</td>
<td>—0.5</td>
<td>1.87</td>
<td>48</td>
</tr>
<tr>
<td>Monnet</td>
<td>2010</td>
<td>1.01</td>
<td>Sepsis-ICU PICCO</td>
<td>160</td>
<td>—0.2</td>
<td>5.4</td>
<td>61</td>
</tr>
<tr>
<td>Opdam</td>
<td>2006</td>
<td>1.03</td>
<td>Cardiac PAC</td>
<td>218</td>
<td>0</td>
<td>2.28</td>
<td>45*</td>
</tr>
<tr>
<td>Sander</td>
<td>2006</td>
<td>1.03</td>
<td>Cardiac PAC</td>
<td>108</td>
<td>0.8</td>
<td>2.80</td>
<td>54</td>
</tr>
<tr>
<td>Breukers</td>
<td>2007</td>
<td>1.03</td>
<td>Cardiac PAC</td>
<td>56</td>
<td>—0.14</td>
<td>2.00</td>
<td>31</td>
</tr>
<tr>
<td>Mayer</td>
<td>2007</td>
<td>1.03</td>
<td>Cardiac PAC</td>
<td>244</td>
<td>0.46</td>
<td>1.15</td>
<td>46</td>
</tr>
<tr>
<td>Sander</td>
<td>2008</td>
<td>1.03</td>
<td>Cardiac PAC</td>
<td>84</td>
<td>0.1</td>
<td>2.20</td>
<td>46*</td>
</tr>
<tr>
<td>Ceconi</td>
<td>2010</td>
<td>1.03</td>
<td>Various-ICU PAC</td>
<td>203</td>
<td>—1.1</td>
<td>3.70</td>
<td>55</td>
</tr>
<tr>
<td>Button</td>
<td>2007</td>
<td>1.07</td>
<td>Cardiac PAC</td>
<td>150</td>
<td>0.25</td>
<td>2.27</td>
<td>54</td>
</tr>
<tr>
<td>Cannesson</td>
<td>2007</td>
<td>1.07</td>
<td>Cardiac PAC</td>
<td>166</td>
<td>—0.26</td>
<td>1.74</td>
<td>38</td>
</tr>
<tr>
<td>Sakka</td>
<td>2007</td>
<td>1.07</td>
<td>Sepsis-ICU PICCO</td>
<td>72</td>
<td>0.5</td>
<td>4.60</td>
<td>68</td>
</tr>
<tr>
<td>Mehta</td>
<td>2008</td>
<td>1.07</td>
<td>Cardiac PAC</td>
<td>96</td>
<td>—0.27</td>
<td>0.44</td>
<td>29</td>
</tr>
<tr>
<td>Staier</td>
<td>2008</td>
<td>1.07</td>
<td>Cardiac PAC</td>
<td>120</td>
<td>0</td>
<td>1.42</td>
<td>36</td>
</tr>
<tr>
<td>Compton</td>
<td>2008</td>
<td>1.07</td>
<td>Various-ICU PICCO</td>
<td>324</td>
<td>0.68</td>
<td>1.94</td>
<td>59</td>
</tr>
<tr>
<td>Bias</td>
<td>2008</td>
<td>1.07</td>
<td>OTLx PAC</td>
<td>400</td>
<td>0.8</td>
<td>2.70</td>
<td>43</td>
</tr>
<tr>
<td>Eleftheriadis</td>
<td>2009</td>
<td>1.07</td>
<td>Cardiac PAC</td>
<td>96</td>
<td>0.4</td>
<td>1.70</td>
<td>34</td>
</tr>
<tr>
<td>Ham</td>
<td>2010</td>
<td>1.07</td>
<td>Cardiac PAC-CCO</td>
<td>6492</td>
<td>—0.1</td>
<td>4.40</td>
<td>46</td>
</tr>
<tr>
<td>Hofer</td>
<td>2010</td>
<td>1.07</td>
<td>Cardiac PAC</td>
<td>156</td>
<td>0.2</td>
<td>2.10</td>
<td>42*</td>
</tr>
<tr>
<td>Jo</td>
<td>2010</td>
<td>1.07</td>
<td>Cardiac PAC</td>
<td>250</td>
<td>—0.07</td>
<td>0.67</td>
<td>26</td>
</tr>
<tr>
<td>Slagt</td>
<td>2010</td>
<td>1.07</td>
<td>Sepsis-ICU PAC</td>
<td>86</td>
<td>—1.6</td>
<td>3.20</td>
<td>48</td>
</tr>
<tr>
<td>Junttila</td>
<td>2010</td>
<td>1.07</td>
<td>ICH-ICU PAC</td>
<td>407</td>
<td>1.5</td>
<td>3.90</td>
<td>58</td>
</tr>
<tr>
<td>Haenggi</td>
<td>2011</td>
<td>1.07</td>
<td>Post-CA PAC</td>
<td>395</td>
<td>0.23</td>
<td>1.28</td>
<td>34</td>
</tr>
<tr>
<td>Saraceni</td>
<td>2011</td>
<td>1.07</td>
<td>Various-ICU PAC</td>
<td>141</td>
<td>—0.18</td>
<td>4.72</td>
<td>67*</td>
</tr>
<tr>
<td>Vetrugno</td>
<td>2011</td>
<td>1.07</td>
<td>Cardiac PAC</td>
<td>360</td>
<td>—0.5</td>
<td>1.70</td>
<td>37</td>
</tr>
<tr>
<td>Prasser</td>
<td>2007</td>
<td>1.1</td>
<td>Cardiac PAC</td>
<td>158</td>
<td>0.01</td>
<td>1.63</td>
<td>26</td>
</tr>
<tr>
<td>Della Rocca</td>
<td>2008</td>
<td>1.1</td>
<td>OTLx PAC</td>
<td>126</td>
<td>0.95</td>
<td>2.82</td>
<td>26</td>
</tr>
<tr>
<td>Mayer</td>
<td>2008</td>
<td>1.1</td>
<td>Cardiac PAC</td>
<td>282</td>
<td>0.19</td>
<td>0.60</td>
<td>24</td>
</tr>
<tr>
<td>Senn</td>
<td>2009</td>
<td>1.1</td>
<td>Cardiac PICCO</td>
<td>200</td>
<td>—0.15</td>
<td>1.60</td>
<td>29</td>
</tr>
<tr>
<td>Biancofiore</td>
<td>2009</td>
<td>1.1</td>
<td>OTLx PAC</td>
<td>290</td>
<td>1.3</td>
<td>2.80</td>
<td>54</td>
</tr>
<tr>
<td>Zimmermann</td>
<td>2009</td>
<td>1.1</td>
<td>Cardiac PAC</td>
<td>138</td>
<td>0.04</td>
<td>2.13</td>
<td>42*</td>
</tr>
<tr>
<td>Hadian</td>
<td>2010</td>
<td>1.1</td>
<td>Cardiac PAC</td>
<td>110</td>
<td>0.43</td>
<td>3.37</td>
<td>59</td>
</tr>
<tr>
<td>Krejci</td>
<td>2010</td>
<td>1.1</td>
<td>OTLx PAC</td>
<td>97</td>
<td>—1.78</td>
<td>2.78</td>
<td>69</td>
</tr>
<tr>
<td>Slagt</td>
<td>2010</td>
<td>1.1</td>
<td>Sepsis-ICU PAC</td>
<td>73</td>
<td>—1.2</td>
<td>2.30</td>
<td>32</td>
</tr>
<tr>
<td>Mutoh</td>
<td>2009</td>
<td>1.1</td>
<td>SAH-ICU PICCO</td>
<td>179</td>
<td>0.57</td>
<td>1.00</td>
<td>25</td>
</tr>
<tr>
<td>Biancofiore</td>
<td>2011</td>
<td>3.02</td>
<td>OTLx PAC</td>
<td>200</td>
<td>0.38</td>
<td>2.33</td>
<td>52</td>
</tr>
<tr>
<td>De Backer</td>
<td>2011</td>
<td>3.02</td>
<td>Sepsis-ICU PAC</td>
<td>401</td>
<td>0</td>
<td>2.20</td>
<td>30</td>
</tr>
<tr>
<td>Metzelder</td>
<td>2011</td>
<td>3.02</td>
<td>SAH-ICU PICCO</td>
<td>158</td>
<td>0.9</td>
<td>2.50</td>
<td>30</td>
</tr>
<tr>
<td>Phan</td>
<td>2012</td>
<td>3.02</td>
<td>Cardiac PAC</td>
<td>44.021</td>
<td>1.13</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>Monnett</td>
<td>2012</td>
<td>3.02</td>
<td>Various-ICU PICCO</td>
<td>60</td>
<td>0.5</td>
<td>3.7</td>
<td>54</td>
</tr>
<tr>
<td>Su</td>
<td>2012</td>
<td>3.02</td>
<td>OTLx PAC</td>
<td>3234</td>
<td>—0.8</td>
<td>4.8</td>
<td>75</td>
</tr>
</tbody>
</table>

Abbreviations: PICCO, transpulmonary thermodilution; Post-CA, post–cardiac arrest; OTLx, orthotopic liver transplant; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage; PAC-CCO, pulmonary artery catheter continuous cardiac output; ICU, intensive care unit.

*Percentage error calculated from data reported in the study.
that in this systematic review, the predictive area under the ROC curve for the PPV was significantly greater than that for the SVV (p < 0.001). This may be related to the fact that a number of assumptions are made in the calculation of the SV (by pulse contour analysis). However, the PPV usually is measured directly from the arterial pressure tracing using advanced digital software. This suggests that the PPV may be the preferred arterial waveform–derived variable when dynamic indices are used for hemodynamic monitoring. This finding is supported by the study of Renner et al. in pediatric patients undergoing cardiac surgery in whom the PPV was highly predictive of fluid responsiveness, whereas the SVV, the central venous pressure, and the global end-diastolic volume index could not distinguish between fluid responders and nonresponders. The SVV/PPV measured by the LiDCO system has been shown to be accurate for the assessment of fluid responsiveness. In a randomized controlled trial by Pearse et al., a significant reduction in complications and a median stay in the hospital were reported in high-risk surgical patients treated with LiDCO-based goal-directed therapy.

Cannesson et al. studied the PPV in 413 patients during general anesthesia and mechanical ventilation using the “gray zone” approach. They identified a range of PPV values between 9% and 13% for which fluid responsiveness could not be predicted accurately. Numerous factors hinder the accuracy of PPV monitoring, most notably ventilator-patient dysynchrony, arrhythmia (particularly atrial fibrillation), low-tidal-volume ventilation, altered chest wall and pulmonary compliance, pulmonary hypertension, and increased intra-abdominal pressure. In routine clinical practice both in the operating room and the intensive care unit, dynamic preload indices may be poor predictors of volume responsiveness.

THORACIC BIOIMPEDANCE

Standard bioimpedance systems apply a high-frequency electric current of known amplitude and frequency across the thorax and measure changes in voltage (amplitude of the returning signal compared with the injected signal). The ratio between voltage and current amplitudes is a measure of transthoracic direct current resistance (more generically referred to as impedance [Zo]), and this varies in proportion to the amount of fluid in the thorax. The instantaneous rate of the change of Zo is believed to be related to the instantaneous blood flow in the aorta. Therefore, the SV is proportional to the product of maximal rate of the change of Zo and ventricular ejection time (VET). Early studies showed a poor agreement between thoracic electrical bioimpedance (TEB) and thermodilution CO. In addition, the accuracy of TEB worsened as the degree of volume overload increased. Newer-generation devices using upgraded computer technology and refined algorithms to calculate CO have produced improved results. However, a poor correlation between TEB-derived CO and that determined by thermodilution in the setting of a cardiac catheterization laboratory was reported. In the Bioimpedance CardioGraphy (BIG) substudy of the ESCAPE heart failure study, there was a poor agreement among TEB and invasively measured hemodynamic profiles. Bioimpedance has been found to be inaccurate in the intensive care unit and other settings in which significant electric noise and body motion exist and in patients with increased lung water. Furthermore, this technique is sensitive to the placement of the electrodes on the body, variations in patient body size, and other physical factors that impact on electric conductivity between the electrodes and the skin (eg, temperature and humidity).

BIOREACTANCE

Because of the limitations of bioimpedance devices, newer methods of processing the impedance signal have been developed. The most promising technology to reach the marketplace is the NICOM device (Cheetah Medical, Portland, OR), which measures the bioimpedance or the phase shift in voltage across the thorax. The human thorax can be described as an electric circuit with a resistor (R) and a capacitor (C), which together create the thoracic impedance (Zo). The values of R and C determine the 2 components of impedance, which are (1) amplitude (a), the magnitude of the impedance (measured in ohms); and (2) phase (phi), the direction of the impedance (measured in degrees). The pulsatile ejection of blood from the heart modifies the value of R and the value of C, leading to instantaneous changes in the amplitude and the phase of Zo. Phase shifts can occur only because of pulsatile flow. The overwhelming majority of thoracic pulsatile flow stems from the aorta. Therefore, the NICOM signal is correlated almost wholly with aortic flow. Furthermore, because the underlying level of thoracic fluid is relatively static, neither the underlying levels of thoracic fluids nor their changes induce any phase shifts and do not contribute to the NICOM signal. The NICOM monitor contains a highly sensitive phase detector that continuously captures thoracic phase shifts, which together result in the NICOM signal (Fig 1).

Unlike many of the other devices reviewed in this article, NICOM is totally noninvasive. This system consists of a high-frequency (75 kHz) sine wave generator and 4 dual-electrode “stickers” that are used to establish electric contact with the body (Fig 2). Within each sticker, 1 electrode is used by the high-frequency current generator to inject the high-frequency sine wave into the body, whereas the other electrode is used by the voltage input amplifier. Two stickers are placed on the right side of the body, and 2 stickers are placed on the left side of the body. The stickers on a given side of the body are paired, so the currents are passed between the outer electrodes of the pair, and voltages are recorded from between the inner electrodes. Thus, a noninvasive CO measurement signal is determined separately from each side of the body, and the final noninvasive CO measurement signal is obtained by averaging these 2 signals. The system’s signal processing unit determines the relative phase shift (∆Φ) between the input and output signals. The peak rate of change of ∆Φ (dΦ/dtmax) is proportional to the peak aortic flow during each beat. The SV is calculated from the following formula: SV = C × VET × dΦ/dtmax, where C is a constant of proportionality and VET is determined from the NICOM and electrocardiographic signals. Unlike bioimpedance, bioimpedance-based CO measurements do not use the static impedance (Zo) and do not depend on the distance between the electrodes for the calculations of SV.
both factors that reduce the reliability of the result. NICOM averages the signal over 1 minute, therefore allowing “accurate” determination of CO in patients with arrhythmias.

The CO as measured by bioreactance has been shown to be highly correlated with that measured by thermodilution and pulse contour analysis. Squarra et al compared the NICOM system with PAC-derived CO in 110 patients after cardiac surgery. The reported bias was +0.16 L/min; the LOA was ±0.04 L/min with a relative error of 9%. The precision of the NICOM system was better than that of thermodilution, with the device being able to track changes in CO accurately. In a study of 3 intensive care units (70 patients), Raval et al reported a bias of −0.09 L/min and an LOA of ±2.4 L/min, with the NICOM system closely tracking changes in the thermodilution CO. Rich et al performed right-heart catheterization in 24 patients with pulmonary hypertension. Simultaneous CO measurements were performed using thermodilution, NICOM, and the Fick methods at baseline and after adenosine vasodilator challenge. CO measured by the NICOM system was significantly more precise than that of thermodilution (3.6% ± 1.7% vs 9.9% ± 5.7%, p < 0.001). Bland-Altman analyses revealed a mean bias and LOA of −0.37 ± 2.6 L/min and 0.21 ± 2.3 L/min, respectively. The adenosine challenge resulted in a similar mean increase in CO with each method. The accuracy of NICOM was assessed in hemodynamically unstable intensive care unit patients and healthy volunteers after passive leg raising (PLR) and fluid challenges (intensive care unit patients) using carotid and brachial arterial Doppler ultrasound flow (mL/min) as the reference technique. In a previous study, almost 100% concordance was found be-

Fig 1. Pulsatile changes in thoracic volume induce phase shifts that are detected continuously by the NICOM’s phase-detection mechanism and captured in the form of the NICOM signal. (Color version of figure is available online.)

Fig 2. The NICOM system and its connection to the body. Four double-electrode stickers are placed around the thorax. A high-frequency current is passed between the 2 outer electrodes, and the resulting voltages are recorded between the 2 inner electrodes. The relative phase shift ($\phi$) and rate of change of phase ($d\phi/dt$) between these signals are determined and used in the calculations of the SV. RF, radiofrequency. (Reproduced with permission from the American Physiological Society.) (Color version of figure is available online.)
tween fluid responsiveness as determined by carotid flow and the NICOM system. Benomar et al showed that the NICOM system could predict fluid responsiveness accurately from changes in CO during PLR. As part of goal-directed perioperative therapy in patients undergoing major surgery, Waldron et al compared fluid responsiveness with an esophageal Doppler monitor and the NICOM system. Notwithstanding the limitations of esophageal Doppler monitoring (as discussed previously), there was a good agreement between these technologies. In this study, hemodynamic variables were not displayed by the esophageal Doppler monitor for 7.8% measurements as compared with 3.7% for the NICOM monitor.

It should be noted that electrocautery interferes with the NICOM signal. However, as long as the device receives a single for at least 20 seconds within a minute, the CO can be determined. When electrocautery is on for more than 40 seconds in a given minute, the CO for that minute is not displayed. NICOM assessment of the CO can be performed in ventilated and nonventilated patients alike; can compute the CO in patients with atrial and ventricular arrhythmias; is very easy to set up with a high degree of acceptability by nursing staff; and can be performed seamlessly in the emergency room, intensive care unit, and operating room. Additional studies with this device are required to confirm the accuracy, reliability, and versatility with this device and to show improved patient outcomes. Figure 3A and B are algorithms using the NICOM monitor that were developed.

![Diagram](image-url)
for the hemodynamic management of septic patients and those in the operating room.

ECHOCARDIOGRAPHY

Although echocardiography traditionally is not considered a monitoring device, both transthoracic and transesophageal echocardiography provide invaluable information on both left and right ventricular function, which is crucial in the management of hemodynamically unstable patients. In addition, a number of dynamic echocardiographic parameters that are based on changes in venacaval dimensions or cardiac function induced by positive-pressure ventilation or PLR appear to be highly predictive of volume responsiveness.

CONCLUSIONS

Although no device is perfect, a number of noninvasive methods to determine the CO in a broad range of patients and settings are now available. The major use of these devices is to optimize fluid resuscitation by determining the patients' re-
response to a PLR maneuver or a fluid challenge. It is important to stress that there are very little data showing that any of these monitoring devices improve patient outcome. In reality, outcomes are changed by the correct interpretation of the data that monitors provide and then instituting the appropriate therapeu-
tic intervention(s). Furthermore, physicians should not blindly follow algorithms and bundles but rather should embrace the patient’s clinical, hemodynamic, laboratory, and radiographic data to chart a course based on the integration and correct interpretation of these data.

REFERENCES

1. Sakr Y, Dubois MJ, De Backer D, et al: Persistent microcirculat-
21. Acker A: Ueber die Messung des Blutquantums in den Herzven-
triekeln. Sitzungsber PhysiologischMedizinische Ges Wuerzburg 2:16, 1870
tion of thermodilution and partial CO2 rebreathing techniques for cardiac output assessment in critically ill patients during assisted ven-
tilation. Intensive Care Med 30:82-87, 2004
28. Nilsson LB, Eldrup N, Berthelsen PG: Lack of agreement be-
31. Binder JC, Parkin WG: Noninvasive cardiac output determina-
tion: Comparison of a new partial-rebreathing technique with thermodi-
invasive partial CO2 rebreathing cardiac output and continuous ther-
34. Tachibana K, Imanaka H, Takeuchi M, et al: Noninvasive car-
diac output measurement using partial carbon dioxide rebreathing is less accurate at settings of reduced minute ventilation and when spontane-
ous breathing is present. Anaesthesiology 98:830-837, 2003
35. Lefrant JY, Bruelle P, Aya AG, et al: Training is required to

60. Manecke GR, Jr, Auger WR: Cardiac output determination from the arterial pressure wave: Clinical testing of a novel algorithm that does not require calibration. J Cardiothorac Vasc Anesth 21:3-7, 2007

